TABLE 3.

IFN-γ responses to P. falciparum-derived peptides in DNA-immunized volunteers

Vaccine componentPeptide codePredicted HLA restrictionSequenceResiduesNo. responders/no. tested (% positive responders)Range of net SFCs/106 PBMCs (geomean)
Defined class I-restricted T epitopes
    PfCSPCSP.A2.386HLA-A2 supertypeGLIMVLSFL386-3941/15 (6.7)70.8
CSP.A2.319HLA-A2.1YLNKIQNSL319-3272/15 (13.3)12-96 (30.3)
CSP.B8.86HLA-B8LRKPKHKKL86-941/5 (20)22.5
    PfSSP2/TRAPSSP.A3.522A3 supertypeLLACAGLAYK522-5311/19 (5.3)23.8
    PfEXP-1EXP.A2.2HLA-A2 supertypeKILSVFFLA2-101/15 (6.7)42.1
EXP.A2.83HLA-A2 supertypeGLLGNVSTV83-913/15 (20)14-17 (15.2)
    PfLSA-1LSA1.A2.1655HLA-A2RLEIPAIEL1655-16632/15 (13.3)12-38 (21.5)
LSA1.A2.4HLA-A2ILYISFYFI4-121/15 (6.7)13-19 (15.3)
LSA1.A3.94HLA-A3 supertypeQTNFKSLLR94-1021/19 (5.3)17.5
LSA1.A3.105HLA-A3 supertypeGVSENIFLK105-1132/19 (10.5)18-41 (26.9)
LSA1.A3.11HLA-A3 supertypeFILVNLLIFH11-202/19 (10.5)16-20 (18.1)
    PfLSA-3LSA3.A2.981HLA-A2.1VLDKVEETV981-989 la261/15 (6.7)14.4
LSA3.A2.113HLA-A2.1DLLEEGNTL113-121 la201/15 (6.7)16.9
Defined or potential class II-restricted T epitopes
    PfCSPCSP.DR/A2.1HLA-DR, A2MMRKLAILSVSSFLFVEALF1-203/31 (9.7)12-23 (17.9)
CSP.DR/A2.318HLA-DR, A2EYLNKIQNSLSTEWSPCSVT318-3375/31 (16.1)13-69 (25.4)
CSP.DR.363HLA-DRDIEKKICKMEKCSSVFNVVNS363-3831/31 (3.2)16.9
CSP.DR/A2.375HLA-DR, A2SSVFNVVNSSIGLIMVLSFLFLN375-3978/31 (25.8)13-28 (21.0)
    PfSSP2/TRAPSSP.DR.223HLA-DRVKNVIGPFMKAVCVE223-2372/31 (6.5)28-30 (29.0)
SSP.DR.527HLA-DRGLAYKFVVPGAATPY527-5414/31 (12.9)16-42 (25.2)
SSP.DR.509HLA-DRKYKIAGGIAGGLALL509-5233/31 (9.7)17-39 (27.0)
    PfEXP-1EXP.DR.82HLA-DRAGLLGNVSTVLLGGV82-963/31 (9.7)21-31 (25.7)
EXP.DR.71HLA-DRKSKYKLATSVLAGLL71-8510/31 (32.3)21-96 (34.0)
    PfLSA-1LSA1.DR.13HLA-DRLVNLLIFHINGKIIKNS13-271/31 (3.2)27.9
LSA1.DR.94HLA-DRQTNFKSLLRNLGVSENIFLK94-1132/31 (6.5)13-25 (16.5)
LSA1.DR.84HLA-DRLTMSNVKNVQTNFKSLLRNLGVS84-107 (T1)3/31 (9.7)19-22 (20.4)
LSA1.DR.1813HLA-DRNENLDDLDEGIEKSSEELSEEKI1813-35 (T3)3/31 (9.7)18-25 (22.5)
LSA1.DR.1888HLA-DRDNEILQIVKELSEKITKYFMKL1888-1909 (T5)3/31 (9.7)19-20 (19.1)
    PfLSA-3LSA3.II.142PotentialLLSNIEEPKENIIDNLLNNI142-161 (CT1)1/31 (3.2)27.5
LSA3.II.200PotentialLEESQVNDDIFNSLVKSVQQEQQHNV200-225 (NRII)1/31 (3.2)13.8